A Pharmaceutical Quality System must do more than describe procedures. It must provide reliable control, clear accountability and evidence that quality risks are understood and managed throughout the product and facility lifecycle.
W2 Cleanroom Consulting provides independent Pharmaceutical Quality System (PQS) support for pharmaceutical manufacturers, NHS aseptic services and regulated organisations across the UK.
We review how the quality system works in practice, identify weak interfaces and help teams build proportionate, inspection-defensible governance.
What Is Pharmaceutical Quality System Support?
PQS support is a structured review and improvement of the processes used to assure product quality and GMP compliance. It connects policies, procedures, records, data, responsibilities and senior-management oversight.
For an introduction to the subject, see What is a Pharmaceutical Quality System?
Core PQS Areas We Review
Quality governance, roles, authorities and escalation
Deviation, investigation and CAPA systems
Change control and maintenance of validated state
Document control and data-integrity governance
Training, competence and effectiveness
Supplier and outsourced-activity oversight
Complaints, recalls and product-quality signals
Self-inspection and internal audit
Product Quality Review and quality metrics
Management review and continual improvement
Finding Weak Interfaces
Many recurring GMP problems sit between systems rather than inside one procedure. A deviation may identify the need for a change, the change may affect validation, validation evidence may alter training, and the combined risk should be visible in management review.
We map these interfaces and test whether information moves reliably between them. This helps prevent disconnected actions, repeated events and closure based on paperwork rather than evidence.
Related guidance covers quality oversight, management review and QMS improvement.
Our PQS Improvement Approach
Define the scope. Confirm products, processes, licences, sites, maturity and current concerns.
Review evidence. Examine procedures, records, metrics, open actions and recent quality events.
Test implementation. Interview responsible people and trace examples through connected systems.
Prioritise risk. Separate material patient, product and compliance weaknesses from lower-value administration.
Design improvement. Set proportionate actions, owners, measures and governance.
Verify effectiveness. Confirm that the change improves decisions, records and performance.
Common Reasons to Strengthen the PQS
Repeat deviations, complaints or CAPA
Inspection observations or audit findings
Growth, acquisition or organisational change
New facilities, products or licensed activities
Fragmented procedures and unclear ownership
Weak quality metrics or management visibility
Backlogs and overdue quality records
Evidence that effectiveness checks are not preventing recurrence
Regulatory Alignment
Our approach is aligned to EU GMP Chapter 1 Pharmaceutical Quality System and applies ICH Q9 quality risk management and ICH Q10 principles where relevant. Other chapters and annexes are considered according to the operation, including Annex 1, Annex 11 and Annex 15.
W2 provides independent consultancy; the client’s authorised Quality function retains approval, disposition, regulatory and licence-holder responsibilities.
Typical Deliverables
PQS gap assessment with risk-ranked findings
Process and responsibility map
Quality-system improvement roadmap
Governance and escalation framework
Quality metrics and management-review pack
Procedure-content and record recommendations
Independent effectiveness or readiness review
Strengthen Your Quality System
W2 can provide a focused assessment of one PQS process or a coordinated programme across the wider quality system. Where immediate operational weaknesses exist, this can be combined with our operational GMP compliance support.
Contact W2 to discuss PQS support or explore the GxP Knowledge Centre.
Prepared and reviewed by: W2 Cleanroom Consulting GMP team. Last reviewed: 24 July 2026.
